"Harnessing 'Good' Bacteria: The $215 Monthly Solution for Diabetes Control"
Biotech startup Pendulum Therapeutics, co-founded by Colleen Cutcliffe, has developed a line of probiotics targeted at gut health, including a flagship product called Glucose Control designed to help diabetics regulate their blood sugar. While the company has raised $126 million in funding and gained traction in the market, its products are marketed as "medical food" and dietary supplements, rather than going through the rigorous FDA approval process as drugs. Pendulum's Glucose Control capsules cost $215 for a monthly supply, and while the company claims efficacy, experts caution that more research is needed on the long-term effects of probiotic supplementation.
